The FDA declined to approve one of biotech's most closely watched cancer drugs

The FDA declined to approve one of biotech's most closely watched cancer drugs

来源:Market Watch发布于 2026-11-16

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

相关标的:SMMT

本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。